Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma
Immunology · 2023-06 · 169 (2) · 204-218
DOI: 10.1111/imm.13624 ↗At a glance
Journal article in Immunology, published online on 2023-01-25. Written by Lin Chen and 6 co-authors. Institution: Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Rep…. Major MEDLINE topics: Carcinoma, Hepatocellular, Receptors, Chimeric Antigen, Liver Neoplasms. Cited 24 times so far (Crossref); 48 references. The full text is freely available in PubMed Central. Funded by: Intramural NIH HHS.
Abstract (original language)
Although the pre‐clinical study of chimeric antigen receptor (CAR)‐natural killer (NK) cell was effective against various tumours, immunosuppression mediated by tumour microenvironment hampers their application and several efforts have been explored to improve their effect in combating solid tumours. Glypican 3 (GPC3) is a promising target for hepatocellular carcinoma (HCC), and CAR‐T cells targeting GPC3 have been tested in clinical trials. Based on an affinity‐enhanced antibody (hYP7) targeting GPC3, we constructed GPC3‐CAR‐NK cells to explore their potential function in the treatment of HCC. We found that patients with HCC secreted high levels of soluble programmed death‐ligand 1 (sPD‐L1), which inhibits the function of CAR‐NK cells targeting GPC3. In addition, we combined high‐affinity sPD‐L1 variant (L3C7c‐Fc) with GPC3‐CAR‐NK cells to solve the problem of GPC3‐CAR‐NK inhibition. Our studies demonstrated that L3C7c‐Fc could enhance the therapeutic effect of CAR‐NK cells by reversing the suppression of sPD‐L1, which provides the experimental evidence for the subsequent development of HCC immunotherapy strategies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Hepatobiliary Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, People's Republic of China.
- Department of Hepatobiliary surgery, Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, People's Republic of China.
- State Key Laboratory of Respiratory Disease, Center of Infection and Immunity, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Science, Guangzhou, People's Republic of China.
- Department of Pathology, Affiliated Drum Tower Hospital, Nanjing Medical University, Nanjing, People's Republic of China.
- Laboratory of Molecular Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.
ORCID profiles: Lin Chen
Funding
- Intramural NIH HHS
Cite
APA
Chen, L., Liu, S., Adah, D., Sun, Q., Liang, Z., Ho, M., & Sun, B. (2023). Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma. Immunology, 169(2), 204-218. https://doi.org/10.1111/imm.13624
Vancouver
Chen L, Liu S, Adah D, Sun Q, Liang Z, Ho M, et al. Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma. Immunology. 2023;169(2):204-218. doi:10.1111/imm.13624
BibTeX
@article{Chen2023,
author = {Chen, Lin and Liu, Siyuan and Adah, Dickson and Sun, Qingyang and Liang, Zhaoduan and Ho, Mitchell and Sun, Beicheng},
title = {Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma},
journal = {Immunology},
year = {2023},
volume = {169},
number = {2},
pages = {204--218},
doi = {10.1111/imm.13624}
}
EUVIMED